Nebivolol Eg (Nebivolol)

Nebivolol works by selectively blocking β1‑adrenergic receptors in the heart, which reduces heart rate and contractility. It also stimulates endothelial nitric‑oxide synthase, causing nitric‑oxide‑mediated vasodilation, together lowering systemic vascular resistance and arterial pressure.

The appropriate dose of Nebivolol Eg is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and any concomitant medications. Dosing regimens are not disclosed here and should follow the prescriber’s instructions.

Safety data for nebivolol during pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit justifies the potential risk to the fetus or infant. Healthcare providers should discuss individual risks with the patient.

To request Nebivolol Eg, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Nebivolol is a highly β1‑selective blocker that also promotes nitric‑oxide‑mediated vasodilation, a property not shared by many older beta blockers. This dual action can result in effective blood‑pressure control with a lower incidence of peripheral vasoconstriction, making it distinct from non‑selective agents.

Nebivolol Eg should be stored at room temperature, below 25 °C, in its original container to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in humid or excessively hot environments.

Nebivolol Eg is administered orally, typically as a tablet taken with or without food. Patients should follow the dosing schedule prescribed by their healthcare professional and should not alter the timing or skip doses without medical advice.

Serious risks include severe bradycardia, marked hypotension, bronchospasm in patients with reactive airway disease, and allergic reactions such as rash or swelling. Patients should seek immediate medical attention if they experience faintness, rapid heartbeat, difficulty breathing, or signs of an allergic response.

Nebivolol should be avoided in patients with known hypersensitivity to nebivolol or any excipients, those with severe bradycardia, second‑ or third‑degree atrioventricular block without a pacemaker, and individuals with uncompensated heart failure or severe hepatic impairment unless specifically directed by a physician.